|
Dr. Henkel joined Ception Therapeutics in January 2006 as Executive Vice President of Research and Development. Tim's biopharmaceutical industry experience includes the development of antibacterial, antifungal, and antiviral drugs, both in the US and Europe. He has developed small molecules, natural products, and biological products. Previously, Tim was Executive V.P. & Chief Medical Officer of Vicuron Pharmaceuticals, where he created their development organization and led the development programs for the company's two late stage products, anidulafungin and dalbavancin. Dr. Henkel joined Vicuron from SmithKline Beecham, where he was V.P. of Worldwide Anti-Infective Clinical Development, based in the U.K. Prior to joining SB, Tim was Assistant Professor of Internal Medicine and Infectious Diseases at Washington University in St. Louis. He earned his board certifications in both Internal Medicine and in Infectious Diseases. Tim was Chief Resident in Internal Medicine at Barnes Hospital following the completion of his fellowship in Infectious Diseases in 1993 and his residency in Internal Medicine in 1990 at the Washington University Medical Center. He earned his MD degree and a PhD in immunology from the Washington University School of Medicine in 1988, and his BS in Chemistry and Biology from Rhodes College in 1981. | 